News | Radiopharmaceuticals and Tracers | September 11, 2015

Zevacor Installs First Medical-only 70 MeV Cyclotron in U.S.

Cyclone 70 to stabilize U.S. supply of Strontium 82, produce next generation of radiopharmaceutical products

Zevacor, IBA, 70 MeV cyclotron, Cyclone 70P, radiopharmaceuticals

September 11, 2015 — Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.

The 140-ton Cyclone 70P, manufactured in Belgium by Ion Beam Applications S.A (IBA), is the first commercial 70 MeV cyclotron dedicated to medical use in the United States. Expected to be fully operational in the first quarter of 2016, the cyclotron is being installed in a new, state-of-the-art high capacity manufacturing center. The center will house a complement of radioisotope synthesis equipment able to produce a broad range of radiopharmaceuticals for clinical and research applications.

The initial primary focus of the 70 MeV cyclotron will be the commercial manufacture of Strontium 82 to ensure an ample, stable U.S.-based supply of Strontium 82/Rubidium 82 generators for use in the diagnosis of cardiovascular disease. The cyclotron will also be employed to produce a wide variety of other radionuclides for both research and clinical applications.

The Cyclone 70P is an optimized, high-power proton cyclotron with variable proton acceleration in the energy range of 30 to 70 MeV. The 140-ton unit has two ports, six beam lines and capabilities for solid, liquid and gas targets.

For more information: www.iba-worldwide.com

Related Content

New Appropriate Use Criteria Outlined for Multimodality Imaging of Nonvalvular Heart Disease
News | Cardiac Imaging | February 11, 2019
The American College of Cardiology (ACC), along with nine other cardiology professional societies, recently published a...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Canon Medical Debuts Alphenix 4-D CT at RSNA 2018
Technology | Angiography | February 06, 2019
Canon Medical Systems USA Inc. recently introduced a new angiography configuration featuring its Alphenix Sky + C-arm...
Canon Medical Systems Launches Alphenix Interventional Imaging Line
Technology | Angiography | February 04, 2019
Canon Medical Systems USA recently introduced its next generation of interventional systems – the Alphenix platform....
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
SCCT Releases New Guideline for CT Use During TAVR
News | Computed Tomography (CT) | January 08, 2019
The Society of Cardiovascular Computed Tomography (SCCT) has released a new expert consensus document for computed...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...